Table 1.
Demographics and clinical characteristic of patients with newly diagnosed inflammatory bowel disease and symptomatic controls.
| Inflammatory bowel diseases [n = 328] | Symptomatic controls [n = 224] | |
|---|---|---|
| Mean age [range], years | 34 [7–78] | 34 [3–79] |
| Males [%] | 172 [52%] | 104 [46%] |
| Smoking status [current: never: ex: missing] | 53:139:107:29 | 48:100:56:20 |
| High sensitivity C-reactive protein (mg/L): median [range] | 22 [0–300] | 5 [0–85] |
| Albumin (g/L): median [range] | 37 [13–50] | 40[29–52] |
| Faecal calprotectin (μg/g): median [range] | 1298 [32–6001] | 78.5 [4–2647] |
| Subtype of IBD | ||
| Crohn’s disease | 146 [45%] | |
| Ulcerative colitis | 153 [47%] | |
| Inflammatory bowel disease unclassified [IBDU] | 29 [8%] | |
| Treatment naïve | 235 [72%] | |
| CD location at diagnosis | ||
| L1 [terminal ileum] | 46 [32%] | |
| L2 [colon] | 43 [29%] | |
| L3 [ileocolon] | 53 [36%] | |
| L4 [upper GI tract] | 4 [3%] | |
| CD behaviour at diagnosis | ||
| B1, B1p [non-stricturing & non-penetrating, +perianal] | 111, 6 [76%, 4%] | |
| B2, B2p [stricturing, +perianal] | 12, 0 [8%, 0%] | |
| B3, B3p [penetrating, +perianal] | 7, 6 [5%, 4%] | |
| Not available | 4 [3%] | |
| Extent of UC at diagnosis | ||
| E1 [proctitis] | 39 [25%] | |
| E2 [left sided] | 47 [31%] | |
| E3 [extensive colitis] | 63 [41%] | |
| Not available | 4 [3%] | |
| Centre | ||
| Edinburgh, UK | 107 | 74 |
| Oslo, Norway | 119 | 60 |
| Orebro, Sweden | 57 | 30 |
| Linkoping, Sweden | 16 | 23 |
| Zaragosa, Spain | 24 | 37 |
| Maastricht, Netherlands | 5 | 0 |
NA, not applicable; CD, Crohn’s disease; UC, ulcerative colitis; IBDU, inflammatory bowel disease unclassified.